Department of Neurosurgery, Abdulkadir Yüksel State Hospital, Gaziantep-Türkiye.
Department of Neurosurgery, Gaziantep University Faculty of Medicine, Gaziantep-Türkiye.
Ulus Travma Acil Cerrahi Derg. 2023 Feb;29(2):155-162. doi: 10.14744/tjtes.2023.33644.
This study aimed to investigate the protective effect of tacrolimus (FK506), an immunosuppressive agent, on secondary brain damage in rats with experimental head trauma.
40 Sprague-Dawley rats, aged 10-12 weeks and weighing 250-350 g, were used without gender selection. The subjects that were divided into five groups of 8 rats per group (sham control, negative control, positive control, vehicle control, and treatment) were sacrificed 1 month after head trauma was induced under appropriate conditions, their brains were then removed en bloc and evaluated histopathologically. Secondary brain injury was evaluated with the immunoreactive score (IRS) after Glial Fibrillary Acid Protein staining of gliosis that would occur in brain tissue.
The evaluation of the histopathological IRS values of all groups showed significant statistical differences between all groups. The pairwise group comparison revealed the highest increase in IRS value in the treatment group (p<0.05), with no statistical significance despite the increase in the negative control, positive control, and vehicle control groups. The sham group had the lowest rate of severe histopathological reaction score.
It was observed that the group treated with FK506 had a statistically significant increase in gliosis in the traumatic area compared to the other control groups. This shows that FK506 cannot prevent and even increase gliosis by a mechanism that has not yet been clarified. In conclusion, it is obvious that the FK506 immunosuppressive agent does not reduce post-traumatic brain injury; on the contrary, it increases gliosis.
本研究旨在探讨免疫抑制剂他克莫司(FK506)对实验性颅脑外伤大鼠继发性脑损伤的保护作用。
选用 10-12 周龄、体重 250-350g 的无性别选择的 Sprague-Dawley 大鼠 40 只。将这些动物分为 5 组,每组 8 只(假手术对照组、阴性对照组、阳性对照组、载体对照组和治疗组)。在适当条件下诱导颅脑外伤后 1 个月处死大鼠,整块取出其大脑,进行组织病理学评估。通过胶质纤维酸性蛋白(GFAP)染色评估神经胶质增生的免疫反应评分(IRS)来评估继发性脑损伤。
对各组的组织病理学 IRS 值评估显示,各组之间存在显著的统计学差异。组间两两比较显示,治疗组 IRS 值增加最高(p<0.05),尽管阴性对照组、阳性对照组和载体对照组 IRS 值也有所增加,但无统计学意义。假手术组的严重组织病理学反应评分最低。
观察到与其他对照组相比,FK506 治疗组创伤区的神经胶质增生有统计学显著增加。这表明 FK506 不能通过尚未阐明的机制预防甚至增加神经胶质增生。总之,FK506 免疫抑制剂不能减轻创伤后脑损伤;相反,它增加了神经胶质增生。